卵巢癌中CA125的免疫测定：三种用于诊断和监测的测定方法的比较

Immunoassay of CA125 in ovarian cancer: a comparison of three assays for use in diagnosis and monitoring.

作者信息

Fisken J, Leonard R C, Roulston J E

机构信息

University Department of Clinical Chemistry, Royal Infirmary, Edinburgh, Scotland, U.K.

出版信息

Dis Markers. 1989 Jan-Mar;7(1):61-7.

PMID:2653700

Abstract

There is increasing evidence to support the use of CA125 in the follow-up and management of patients with ovarian cancer and several commercial kits are now available for its measurement. This study investigated and compared the performance of three of them: an enzyme immunoassay (EIA) and an immunoradiometric assay (IRMA) from Abbott Diagnostics, and an IRMA from CIS, U.K. One hundred and thirty-two serum samples from 42 patients with advanced epithelial ovarian cancer were thawed once and assayed for CA125 using each kit. Both IRMAs performed better than the EIA in terms of CV, sensitivity, specificity, and accuracy. The results confirm the usefulness of CA125 as a marker for ovarian cancer. However, discrepancies between results using different kits suggest the need for improved standardization.

摘要

越来越多的证据支持CA125用于卵巢癌患者的随访和管理，目前有几种商用试剂盒可用于其检测。本研究调查并比较了其中三种试剂盒的性能：雅培诊断公司的酶免疫测定法（EIA）和免疫放射测定法（IRMA），以及英国CIS公司的IRMA。对42例晚期上皮性卵巢癌患者的132份血清样本解冻一次，使用每种试剂盒检测CA125。在变异系数、敏感性、特异性和准确性方面，两种IRMA的表现均优于EIA。结果证实了CA125作为卵巢癌标志物的有用性。然而，不同试剂盒检测结果之间的差异表明需要改进标准化。